Brian T. Hill, MD, PhD

Experts discussed the ZUMA-2 clinical trial of brexucabtagene autoleucel.

Doctors from University of Washington and Cleveland Clinic discussed targeting CD19 in CAR T-cell therapy for relapsed/refractory DLBCL.

Brian T. Hill, MD, PhD, discusses next steps for research examining CAR T-cell therapy in mantle cell lymphoma.

Brian T. Hill, MD, PhD, discusses future research with CAR T-cell therapy in hematologic malignancies.

Brian T. Hill, MD, PhD, discusses the management of cytokine release syndrome in patients with hematologic malignancies who are treated with CAR T-cell therapy.

Brian T. Hill, MD, PhD, discusses the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.